Literature DB >> 23007594

Chimeric G proteins in fluorimetric calcium assays: experience with opioid receptors.

Valeria Camarda1, Girolamo Calo'.   

Abstract

High throughput calcium mobilization assays are extensively used for pharmacological characterization of GPCR ligands. These approaches, initially developed for G(q)-coupled receptors, can be extended to G(i) coupled GPCRs using chimeric G proteins. Here we used the Gα(qi5) protein to force the nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor, as well as the classical opioid receptors to signal through the PLC-IP(3)-Ca(2+) pathway in CHO cells. Calcium levels were monitored using the fluorometric imaging plate reader FlexStation II and the Ca(2+) dye Fluo 4 AM. For investigating the pharmacology of the NOP receptor a panel of full and partial agonists and antagonists were assessed, while a small panel of agonists and antagonists was used for evaluating the pharmacological profile of opioid receptors. Some limitations of this assay and differences in the results obtained in comparison with those with G(i) based biochemical assays are described. Overall, the present results confirm that the chimeric G protein strategy is useful for studying the pharmacological activity of G(i) coupled receptor ligands and that the aberrant signaling does not produce any measurable change in the pharmacological profile of the receptor under study. Thus, this G protein strategy is extremely useful for setting up primary screening assays for NOP and classical opioid receptors and likely for other members of the GPCR family.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23007594     DOI: 10.1007/978-1-62703-086-1_18

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  18 in total

1.  Synthesis of mixed opioid affinity cyclic endomorphin-2 analogues with fluorinated phenylalanines.

Authors:  Justyna Piekielna; Renata Perlikowska; Jean Claude do-Rego; Jean-Luc do-Rego; Maria Camilla Cerlesi; Girolamo Calo; Alicja Kluczyk; Krzysztof Łapiński; Csaba Tömböly; Anna Janecka
Journal:  ACS Med Chem Lett       Date:  2015-04-03       Impact factor: 4.345

2.  Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt1]N/OFQ(1-13).

Authors:  Maria Camilla Cerlesi; Huiping Ding; Mark F Bird; Norikazu Kiguchi; Federica Ferrari; Davide Malfacini; Anna Rizzi; Chiara Ruzza; David G Lambert; Mei-Chuan Ko; Girolamo Calo; Remo Guerrini
Journal:  Eur J Pharmacol       Date:  2016-11-19       Impact factor: 4.432

3.  [Dmt1]N/OFQ(1-13)-NH2: a potent nociceptin/orphanin FQ and opioid receptor universal agonist.

Authors:  S Molinari; V Camarda; A Rizzi; G Marzola; S Salvadori; E Marzola; P Molinari; J McDonald; M C Ko; D G Lambert; G Calo'; R Guerrini
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

4.  In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives.

Authors:  A Rizzi; D Malfacini; M C Cerlesi; C Ruzza; E Marzola; M F Bird; D J Rowbotham; S Salvadori; R Guerrini; D G Lambert; G Calo
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

5.  In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations.

Authors:  Federica Ferrari; Maria Camilla Cerlesi; Davide Malfacini; Laila Asth; Elaine C Gavioli; Blair V Journigan; Uma Gayathri Kamakolanu; Michael E Meyer; Dennis Yasuda; Willma E Polgar; Anna Rizzi; Remo Guerrini; Chiara Ruzza; Nurulain T Zaveri; Girolamo Calo
Journal:  Eur J Pharmacol       Date:  2016-10-22       Impact factor: 4.432

6.  Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo).

Authors:  Mark F Bird; Maria Camilla Cerlesi; Mark Brown; Davide Malfacini; Vanessa Vezzi; Paola Molinari; Laura Micheli; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Remo Guerrini; Girolamo Calò; David G Lambert
Journal:  PLoS One       Date:  2016-06-07       Impact factor: 3.240

7.  A diastereoselective synthesis of Cebranopadol, a novel analgesic showing NOP/mu mixed agonism.

Authors:  Anna Fantinati; Sara Bianco; Remo Guerrini; Severo Salvadori; Salvatore Pacifico; Maria Camilla Cerlesi; Girolamo Calo; Claudio Trapella
Journal:  Sci Rep       Date:  2017-05-25       Impact factor: 4.379

8.  Hyaluronic acid induces activation of the κ-opioid receptor.

Authors:  Barbara Zavan; Letizia Ferroni; Carlotta Giorgi; Girolamo Calò; Paola Brun; Roberta Cortivo; Giovanni Abatangelo; Paolo Pinton
Journal:  PLoS One       Date:  2013-01-28       Impact factor: 3.240

9.  Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptor.

Authors:  Tanila Ben Haddou; Davide Malfacini; Girolamo Calo; Mario D Aceto; Louis S Harris; John R Traynor; Andrew Coop; Helmut Schmidhammer; Mariana Spetea
Journal:  Mol Pain       Date:  2014-07-24       Impact factor: 3.395

10.  Pharmacological investigations of N-substituent variation in morphine and oxymorphone: opioid receptor binding, signaling and antinociceptive activity.

Authors:  Tanila Ben Haddou; Szabolcs Béni; Sándor Hosztafi; Davide Malfacini; Girolamo Calo; Helmut Schmidhammer; Mariana Spetea
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.